Immunic (NASDAQ:IMUX) Now Covered by HC Wainwright

Equities researchers at HC Wainwright started coverage on shares of Immunic (NASDAQ:IMUX) in a note issued to investors on Monday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $10.00 price target on the stock.

Other equities analysts have also recently issued research reports about the stock. Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, September 9th. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. EF Hutton Acquisition Co. I raised Immunic to a “strong-buy” rating in a research report on Monday, September 16th. B. Riley started coverage on Immunic in a research report on Tuesday, August 27th. They set a “buy” rating and a $6.00 price target on the stock. Finally, Leerink Partners reiterated an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $11.80.

Immunic Stock Down 0.9 %

NASDAQ:IMUX opened at $1.10 on Monday. Immunic has a twelve month low of $0.97 and a twelve month high of $2.11. The stock has a market cap of $99.09 million, a P/E ratio of -0.89 and a beta of 1.88. The firm’s fifty day simple moving average is $1.40 and its 200 day simple moving average is $1.34.

Insider Buying and Selling

In related news, Director Richard Alan Rudick purchased 87,300 shares of Immunic stock in a transaction dated Tuesday, November 12th. The stock was purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the purchase, the director now directly owns 87,300 shares of the company’s stock, valued at $100,395. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 3.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Immunic

A number of large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Immunic during the 1st quarter valued at $25,000. Jane Street Group LLC lifted its position in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the period. State Street Corp increased its position in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares in the last quarter. Finally, Ikarian Capital LLC lifted its holdings in shares of Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after buying an additional 1,162,378 shares in the last quarter. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.